Slingshot members are tracking this event:

Celgene Releases Interim Analyses on Endpoints in Phase 3 ABOUND Study of ABRAXANE on Patients with Non-Small Cell Lung Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data In the study, "The first analysis evaluated the therapeutic impact of chemotherapy on patient symptoms and activities." Quality of life was generally either maintained or improved throughout the entire treatment course.  "The second analysis assessed the impact of radiological response on Quality of Life."  38 - 47% reported complete resolution of problems resulting from the condition at least once during treatment. This was more pronounced in patients who achieved a radiological response, with complete resolution at least once reported in 42 - 59% of patients.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 27, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Interim Analysis, Abound Study, Abraxane, Non-small Cell Lung Cancer